Vorozole

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Vorozole
Vorozole.svg
Systematic (IUPAC) name
6-[(4-Chlorophenyl)(1,2,4-triazol-1-yl)methyl]-1-methylbenzotriazole
Pharmacokinetic data
Bioavailability Very high
Metabolism Hepatic
Biological half-life 8 hours
Identifiers
CAS Registry Number 118949-22-7 N
ATC code L02BG05
PubChem CID: 6918191
ChemSpider 5293402 YesY
UNII 1E2S9YXV2A YesY
KEGG D03786 YesY
ChEMBL CHEMBL224060 YesY
Chemical data
Formula C16H13ClN6
Molecular mass 324.768 g/mol
 N (what is this?)  (verify)

Vorozole is an imidazole based competitive inhibitor of the aromatase enzyme. It underwent clinical testing for evaluation for use as an antineoplastic agent; however it was withdrawn from testing when no difference was detected in the duration of median survival as compared to the progestational agent megestrol acetate and research instead focused on the other third generation aromatase inhibitors anastrozole, letrozole and exemestane.

It is selective.[1]

References[edit]

  1. ^ Goss PE (1998). "Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor" (PDF). Breast Cancer Res. Treat. 49. Suppl 1: S59–65; discussion S73–7. doi:10.1023/a:1006052923468. PMID 9797019.